Detalhe da pesquisa
1.
The Metabolism and Disposition of Brepocitinib in Humans and Characterization of the Formation Mechanism of an Aminopyridine Metabolite.
Drug Metab Dispos
; 2024 May 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-38719744
2.
A phase 1 study to investigate the absorption, distribution, metabolism and excretion of brepocitinib in healthy males using a 14 C-microdose approach.
Br J Clin Pharmacol
; 89(10): 3056-3066, 2023 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-37183779
3.
Utilization of Rosuvastatin and Endogenous Biomarkers in Evaluating the Impact of Ritlecitinib on BCRP, OATP1B1, and OAT3 Transporter Activity.
Pharm Res
; 40(11): 2639-2651, 2023 Nov.
Artigo
em Inglês
| MEDLINE | ID: mdl-37561322
4.
Ritlecitinib and brepocitinib demonstrate significant improvement in scalp alopecia areata biomarkers.
J Allergy Clin Immunol
; 149(4): 1318-1328, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34863853
5.
The Pharmacokinetics, Metabolism, and Clearance Mechanisms of Abrocitinib, a Selective Janus Kinase Inhibitor, in Humans.
Drug Metab Dispos
; 50(8): 1106-1118, 2022 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-35701182
6.
Design and optimization of a series of 4-(3-azabicyclo[3.1.0]hexan-3-yl)pyrimidin-2-amines: Dual inhibitors of TYK2 and JAK1.
Bioorg Med Chem
; 28(10): 115481, 2020 05 15.
Artigo
em Inglês
| MEDLINE | ID: mdl-32253095
7.
Clearance Prediction of Targeted Covalent Inhibitors by In Vitro-In Vivo Extrapolation of Hepatic and Extrahepatic Clearance Mechanisms.
Drug Metab Dispos
; 45(1): 1-7, 2017 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-27784718
8.
The mechanism of action of tofacitinib - an oral Janus kinase inhibitor for the treatment of rheumatoid arthritis.
Clin Exp Rheumatol
; 34(2): 318-28, 2016.
Artigo
em Inglês
| MEDLINE | ID: mdl-26966791
9.
Preclinical to clinical translation of tofacitinib, a Janus kinase inhibitor, in rheumatoid arthritis.
J Pharmacol Exp Ther
; 348(1): 165-73, 2014 Jan.
Artigo
em Inglês
| MEDLINE | ID: mdl-24218541
10.
The pharmacokinetics, metabolism, and clearance mechanisms of tofacitinib, a janus kinase inhibitor, in humans.
Drug Metab Dispos
; 42(4): 759-73, 2014 Apr.
Artigo
em Inglês
| MEDLINE | ID: mdl-24464803
11.
Virtual Bioequivalence Assessment of Ritlecitinib Capsules with Incorporation of Observed Clinical Variability Using a Physiologically Based Pharmacokinetic Model.
AAPS J
; 26(1): 17, 2024 01 24.
Artigo
em Inglês
| MEDLINE | ID: mdl-38267790
12.
Integrating Clinical Variability into PBPK Models for Virtual Bioequivalence of Single and Multiple Doses of Tofacitinib Modified-Release Dosage Form.
Clin Pharmacol Ther
; 2024 May 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-38797995
13.
Assessment of the Effects of Abrocitinib on the Pharmacokinetics of Probe Substrates of Cytochrome P450 1A2, 2B6 and 2C19 Enzymes and Hormonal Oral Contraceptives in Healthy Individuals.
Eur J Drug Metab Pharmacokinet
; 49(3): 367-381, 2024 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-38554232
14.
Modulation of innate and adaptive immune responses by tofacitinib (CP-690,550).
J Immunol
; 186(7): 4234-43, 2011 Apr 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-21383241
15.
Evaluation of the Impact of Ritlecitinib on Organic Cation Transporters Using Sumatriptan and Biomarkers as Probes.
J Clin Pharmacol
; 63(7): 784-797, 2023 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-36807251
16.
Lack of effect of tofacitinib (CP-690,550) on the pharmacokinetics of the CYP3A4 substrate midazolam in healthy volunteers: confirmation of in vitro data.
Br J Clin Pharmacol
; 74(1): 109-15, 2012 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-22233204
17.
Population Pharmacokinetics of Oral Brepocitinib in Healthy Volunteers and Patients.
Clin Pharmacol Drug Dev
; 11(12): 1447-1456, 2022 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-36045513
18.
A Phase 1 Study to Assess Mass Balance and Absolute Bioavailability of Zimlovisertib in Healthy Male Participants Using a 14 C-Microtracer Approach.
Clin Pharmacol Drug Dev
; 11(7): 815-825, 2022 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-35506501
19.
Effects of Renal Impairment on the Pharmacokinetics of Abrocitinib and Its Metabolites.
J Clin Pharmacol
; 62(4): 505-519, 2022 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-34637151
20.
Assessment of the Effects of Inhibition or Induction of CYP2C19 and CYP2C9 Enzymes, or Inhibition of OAT3, on the Pharmacokinetics of Abrocitinib and Its Metabolites in Healthy Individuals.
Eur J Drug Metab Pharmacokinet
; 47(3): 419-429, 2022 May.
Artigo
em Inglês
| MEDLINE | ID: mdl-35226304